We have broad based research efforts spanning across a number of therapeutic areas.
CGeneTech is currently pursuing research programs in the following principal areas: cardiovascular and diabetes. In all of these programs, we have identified targets and compounds with demonstrated in vitro and, in some cases, in vivo activity.
Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates.
CGeneTech is conducting clinical and preclinical studies in its core focus areas, which include the following:
ESP-8509 recently completed
ESP-9085 recently completed target identification and design.
ESP-8012 completed target identification, screening, lead modification, SAR, in-vitro studies. ?Applied China and US patent.
In addition to the areas noted above, CGeneTech is continuing to explore the human genome to identify new therapeutic opportunities.